AR065805A1 - Una composicion proliposomal de drogas y compuestos con escasa solubilidad en agua y un proceso para preparar la composicion proliposomal - Google Patents
Una composicion proliposomal de drogas y compuestos con escasa solubilidad en agua y un proceso para preparar la composicion proliposomalInfo
- Publication number
- AR065805A1 AR065805A1 ARP080101166A ARP080101166A AR065805A1 AR 065805 A1 AR065805 A1 AR 065805A1 AR P080101166 A ARP080101166 A AR P080101166A AR P080101166 A ARP080101166 A AR P080101166A AR 065805 A1 AR065805 A1 AR 065805A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- drugs
- water solubility
- agents
- proliposomal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 229940079593 drug Drugs 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 abstract 4
- 239000012141 concentrate Substances 0.000 abstract 3
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 abstract 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 abstract 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 abstract 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 abstract 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 abstract 1
- 229930192392 Mitomycin Natural products 0.000 abstract 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 239000002535 acidifier Substances 0.000 abstract 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
- 229960003942 amphotericin b Drugs 0.000 abstract 1
- 229940035674 anesthetics Drugs 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000003474 anti-emetic effect Effects 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229940125683 antiemetic agent Drugs 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 229960000830 captopril Drugs 0.000 abstract 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 1
- HVTXSOUPDUVALO-MJDVJXEKSA-N chembl450152 Chemical compound C1=CC=C2C(C[C@]3(C)[C@H]4CC[C@H]5[C@@]([C@@]4(CC[C@H]3C3(C)C)C)(C)CC[C@]4(CC[C@H]([C@H]54)C(=C)C)C(=O)NCC(O)=O)=C3NC2=C1 HVTXSOUPDUVALO-MJDVJXEKSA-N 0.000 abstract 1
- COOOTKBYWXVUIA-HIFHRDMOSA-N chembl470793 Chemical compound C1=C(Cl)C=C2C(C[C@]3(C)[C@H]4CC[C@H]5[C@@]([C@@]4(CC[C@H]3C3(C)C)C)(C)CC[C@]4(CC[C@H]([C@H]54)C(=C)C)C(O)=O)=C3NC2=C1 COOOTKBYWXVUIA-HIFHRDMOSA-N 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- -1 ethoposide Chemical compound 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004675 fusidic acid Drugs 0.000 abstract 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 abstract 1
- 239000003193 general anesthetic agent Substances 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 abstract 1
- 229960003727 granisetron Drugs 0.000 abstract 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 abstract 1
- 229960002456 hexobarbital Drugs 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 229960000905 indomethacin Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 229960004125 ketoconazole Drugs 0.000 abstract 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 abstract 1
- 229960000991 ketoprofen Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000000936 membranestabilizing effect Effects 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 229960000282 metronidazole Drugs 0.000 abstract 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 abstract 1
- 229960003632 minoxidil Drugs 0.000 abstract 1
- 229960004857 mitomycin Drugs 0.000 abstract 1
- 229960002009 naproxen Drugs 0.000 abstract 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 abstract 1
- 229960005343 ondansetron Drugs 0.000 abstract 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 229960002702 piroxicam Drugs 0.000 abstract 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 abstract 1
- 229960005205 prednisolone Drugs 0.000 abstract 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 abstract 1
- 229960004134 propofol Drugs 0.000 abstract 1
- 229960003401 ramipril Drugs 0.000 abstract 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960002871 tenoxicam Drugs 0.000 abstract 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 abstract 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 abstract 1
- 229960001693 terazosin Drugs 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 229960000303 topotecan Drugs 0.000 abstract 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- XQDCKJKKMFWXGB-UHFFFAOYSA-N wedelolactone Chemical compound O1C2=CC(O)=C(O)C=C2C2=C1C1=C(O)C=C(OC)C=C1OC2=O XQDCKJKKMFWXGB-UHFFFAOYSA-N 0.000 abstract 1
- RFQPHWCAHNTCDX-UHFFFAOYSA-N wedelolactone Natural products COc1cc(O)cc2OC(=O)c3c(oc4cc(O)c(O)cc34)c12 RFQPHWCAHNTCDX-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Concentrados o composiciones proliposomales de drogas y compuestos con escasa solubilidad en agua, que comprenden uno o más lípidos formadores de membrana, un agente estabilizador de membrana, en un vehículo adecuado, y que opcionalmente contiene un fosfolípido acoplado a polietilenglicol (PEG) o una mezcla de dichos compuestos y, además, opcionalmente contiene excipientes farmacéuticamente aceptables tales como antioxidantes, agentes tampon, agentes acidificantes, etc.; estos concentrados o composiciones proliposomales tienen una estabilidad superior a largo plazo. Los concentrados o composiciones proliposomales forman instantáneamente liposomas de dichas drogas y compuestos con escasa solubilidad en agua después de su inyeccion rápida a un fluido diluyente; la composicion liposomal obtenida de este modo se caracteriza por una estabilidad física de más de 24 horas, l 95% de encapsulamiento de la droga y por tener un diámetro de partícula de menos de 100 nm. Las composiciones liposomales obtenidas de este modo asimismo pueden administrarse directamente a pacientes que necesiten tratamiento con dichas drogas que son compuestos con escasa solubilidad en agua. Procesos para prepararla. Reivindicacion 4: La composicion de acuerdo con la reivindicacion 1 caracterizada porque las drogas y compuestos con escasa solubilidad en agua pertenecen a la clase de agentes anticancerígenos, seleccionados de entre paclitaxel, docetaxel, irinotecan, topotecan, SN-38, doxorubicina, daunomicina, cisplatino, oxaliplatino, 5-fluorouracilo, mitomicina, metotrexato, etoposida, wedelolactona y sus derivados, ácido betulínico, derivado del ácido betulínico, MJ-1098 de la formula (1); derivado del ácido betulínico, DRF-4012 de la formula (2); o derivado del ácido betulínico, DRF-4015 de la formula (3), agentes antiinflamatorios, seleccionados de indometacina, ibuprofeno, ketoprofeno, flubiprofeno, piroxicam, tenoxicam o naproxen, agentes antifungicos, seleccionados de ketoconazol, o anfotericina B; hormonas sexuales, seleccionadas de testosterona, estrogeno, progesterona o estradiol; esteroides, seleccionados de dexametasona, prednisolona, fulvestrantexemestano o triamcinolona; agentes antihipertensivos, seleccionados de captopril, ramipril, terazosin, minoxidil o parazosin; antieméticos, seleccionados de ondansetron o granisetron; antibioticos, seleccionados de metronidazol o ácido fusídico; inmunomoduladores, seleccionados de ciclosporina o ácido bifenil dimetil dicarboxílico; y anestésicos, seleccionados de propofol, a-xalona o hexobarbital.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN590DE2007 | 2007-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065805A1 true AR065805A1 (es) | 2009-07-01 |
Family
ID=39620132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101166A AR065805A1 (es) | 2007-03-19 | 2008-03-19 | Una composicion proliposomal de drogas y compuestos con escasa solubilidad en agua y un proceso para preparar la composicion proliposomal |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090017105A1 (es) |
| EP (1) | EP2146692A1 (es) |
| AR (1) | AR065805A1 (es) |
| AU (1) | AU2008227852B2 (es) |
| CA (1) | CA2681302C (es) |
| CL (1) | CL2008000786A1 (es) |
| TW (1) | TWI355946B (es) |
| WO (1) | WO2008114274A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8476010B2 (en) | 2003-07-10 | 2013-07-02 | App Pharmaceuticals Llc | Propofol formulations with non-reactive container closures |
| US20140335166A1 (en) * | 2013-05-08 | 2014-11-13 | Michael W. Fountain | Methods of Making and Using Nano Scale Particles |
| KR101066197B1 (ko) * | 2009-04-06 | 2011-09-20 | 한국생명공학연구원 | 코엔자임 ｑ10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물 |
| PL214538B1 (pl) * | 2009-05-28 | 2013-08-30 | P P F Hasco Lek Spolka Akcyjna | Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen |
| US20110070293A1 (en) * | 2009-09-23 | 2011-03-24 | Javeri Indu | Methods for the Preparation of Liposomes Comprising Docetaxel |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| PL2508170T3 (pl) | 2009-12-03 | 2015-12-31 | Jiangsu Hengrui Medicine Co | Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania |
| JP5824511B2 (ja) | 2010-05-03 | 2015-11-25 | テイコク ファーマ ユーエスエー インコーポレーテッド | 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法 |
| AU2013259509B2 (en) * | 2012-05-09 | 2017-09-07 | Tesorx Pharma, Llc | Proliposomal testosterone formulations |
| IN2014MN02213A (es) * | 2012-05-10 | 2015-07-10 | Painreform Ltd | |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| CN103768018A (zh) * | 2012-10-17 | 2014-05-07 | 南京绿叶思科药业有限公司 | 一种卡巴他赛脂质体注射剂及其制备方法 |
| US20150132369A1 (en) * | 2013-11-09 | 2015-05-14 | Exir Nano Sina Company | Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof |
| EP3265059A4 (en) * | 2015-03-03 | 2018-08-29 | Cureport Inc. | Combination liposomal pharmaceutical formulations |
| CA2977397A1 (en) * | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| MX381475B (es) | 2015-08-20 | 2025-03-12 | Ipsen Biopharm Ltd | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. |
| CN105055322A (zh) * | 2015-09-02 | 2015-11-18 | 厦门市壳聚糖生物科技有限公司 | 甲氨喋呤磷脂复合物、其纳米粒子及其靶向缓释制剂三者的制备方法 |
| US20180280300A1 (en) * | 2015-10-07 | 2018-10-04 | Ensuiko Sugar Refining Co., Ltd. | Liposome including taxane compound |
| KR20180101452A (ko) * | 2016-01-08 | 2018-09-12 | 웨스턴 유니버시티 오브 헬스 사이언시스 | 프로리포솜성 테스토스테론 운데카노에이트 제제 |
| CN107362142B (zh) * | 2016-05-13 | 2023-04-25 | 山东新时代药业有限公司 | 一种氟维司群脂质体注射液及其制备方法 |
| KR20190067172A (ko) * | 2016-09-09 | 2019-06-14 | 아이리시스, 인크. | 리포좀 항암 조성물 |
| HRP20220952T1 (hr) | 2016-10-28 | 2022-10-28 | Les Laboratoires Servier | Liposomalna formulacija za korištenje kod liječenja raka |
| BR112019009616A2 (pt) | 2016-11-11 | 2019-08-13 | Western University Of Health Sciences | métodos de tratamento de carcinomas uroteliais do trato superior |
| CN108926533B (zh) * | 2017-05-24 | 2022-03-25 | 江苏天士力帝益药业有限公司 | 一种替西罗莫司脂质体及其制备方法 |
| WO2019082139A1 (en) * | 2017-10-27 | 2019-05-02 | Shilpa Medicare Limited | LIPOSOMAL FINGOLIMOD HYDROCHLORIDE INJECTION |
| RU2752417C1 (ru) * | 2017-11-30 | 2021-07-28 | Схилпа Медикаре Лимитед | Композиция на основе липосомальной формы доцетаксела для инъекций с высоким содержанием лекарственного средства |
| CN110368500B (zh) * | 2019-07-12 | 2020-06-30 | 浙江大学 | 一种两亲性共聚物药物前体、制备方法以及包载钙泊三醇的纳米颗粒 |
| CN112076158B (zh) * | 2020-08-28 | 2023-12-08 | 西南民族大学 | 一种治疗慢性肾炎的脂质体-纳米粒复合体 |
| CN113181113A (zh) * | 2021-04-28 | 2021-07-30 | 四川科伦药业股份有限公司 | 一种甲硝唑氯化钠注射液的制备方法 |
| CN119857064B (zh) * | 2025-03-25 | 2025-06-24 | 广州市芊彩化妆品有限公司 | 一种深层滋养的护发素及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744989A (en) * | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| DE3585967D1 (de) * | 1984-03-08 | 1992-06-11 | Phares Pharma Holland | Liposombildende zusammensetzung. |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5262168A (en) * | 1987-05-22 | 1993-11-16 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
| ES2087151T3 (es) * | 1989-03-31 | 1996-07-16 | Univ California | Preparacion de composiciones complejas de liposomas y lipidos. |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| EP0707472B1 (en) * | 1993-07-08 | 2001-03-14 | The Liposome Company, Inc. | Method of controlling the size of liposomes |
| SA95160463B1 (ar) * | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | مساحيق للاستنشاق |
| US5753262A (en) * | 1995-06-07 | 1998-05-19 | Aronex Pharmaceuticals, Inc. | Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof |
| GB2331924A (en) * | 1997-12-08 | 1999-06-09 | Phares Pharm Res Nv | Lipid compositions and their use |
| ES2256043T3 (es) * | 1999-10-01 | 2006-07-16 | Lipoxen Technologies Limited | Vacunas de uso oral que contienen liposomas y adn atrapado. |
| US6761901B1 (en) * | 2000-05-02 | 2004-07-13 | Enzrel Inc. | Liposome drug delivery |
| EP1530465B2 (en) * | 2002-06-26 | 2015-12-16 | MediGene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| CA2506749A1 (en) * | 2002-11-26 | 2004-06-10 | Gilead Sciences, Inc. | Method of drug loading in liposomes by gradient |
| EA200501285A1 (ru) * | 2003-02-11 | 2006-02-24 | Неофарм, Инк. | Способ получения липосомальных препаратов |
| JP4804923B2 (ja) * | 2003-09-03 | 2011-11-02 | 協和発酵キリン株式会社 | グリセロール誘導体で修飾された化合物 |
| UA86063C2 (ru) * | 2004-05-03 | 2009-03-25 | Хермес Біосайенсез, Інк. | Липосомы для снабжения лекарств |
| EP2007355A2 (en) * | 2005-12-08 | 2008-12-31 | Wyeth a Corporation of the State of Delaware | Liposomal compositions |
| US9814672B2 (en) * | 2007-03-09 | 2017-11-14 | Susan T. Laing | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi |
-
2008
- 2008-01-04 EP EP08702731A patent/EP2146692A1/en not_active Withdrawn
- 2008-01-04 AU AU2008227852A patent/AU2008227852B2/en not_active Ceased
- 2008-01-04 CA CA2681302A patent/CA2681302C/en not_active Expired - Fee Related
- 2008-01-04 WO PCT/IN2008/000003 patent/WO2008114274A1/en not_active Ceased
- 2008-03-10 TW TW097108323A patent/TWI355946B/zh not_active IP Right Cessation
- 2008-03-11 US US12/045,958 patent/US20090017105A1/en not_active Abandoned
- 2008-03-18 CL CL200800786A patent/CL2008000786A1/es unknown
- 2008-03-19 AR ARP080101166A patent/AR065805A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI355946B (en) | 2012-01-11 |
| US20090017105A1 (en) | 2009-01-15 |
| EP2146692A1 (en) | 2010-01-27 |
| CA2681302A1 (en) | 2008-09-25 |
| TW200904483A (en) | 2009-02-01 |
| AU2008227852A1 (en) | 2008-09-25 |
| CL2008000786A1 (es) | 2008-09-26 |
| AU2008227852B2 (en) | 2011-02-24 |
| CA2681302C (en) | 2013-07-23 |
| WO2008114274A1 (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065805A1 (es) | Una composicion proliposomal de drogas y compuestos con escasa solubilidad en agua y un proceso para preparar la composicion proliposomal | |
| KR101875263B1 (ko) | 디에틸렌 글리콜 모노에틸에테르 또는 다른 알킬 유도체를 포함하는 약학적 활성제의 조성물 | |
| ES2784307T3 (es) | Besifloxacina para el tratamiento del acné resistente | |
| Sengupta et al. | Potential and future scope of nanoemulgel formulation for topical delivery of lipophilic drugs | |
| Lu et al. | Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice | |
| AR077338A1 (es) | Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion. | |
| MX2022006258A (es) | Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina. | |
| WO2011082384A3 (en) | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols | |
| NZ631833A (en) | Emulsion formulations | |
| NZ599523A (en) | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | |
| UA113549C2 (xx) | Біорозкладений засіб доставки лікарських засобів для гідрофобних композицій | |
| NZ596657A (en) | Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof | |
| Koudelka et al. | Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect | |
| AR122024A1 (es) | Formulaciones de liposomas para el tratamiento de cánceres y de la resistencia a los medicamentos de los cánceres | |
| JP2016531895A5 (es) | ||
| Chen et al. | Microemulsion: a novel transdermal delivery system to facilitate skin penetration of indomethacin | |
| WO2011130834A8 (en) | Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof | |
| ES2771423T3 (es) | Composición de cabazitaxel | |
| MX345888B (es) | Emulsion aceite en agua de mometasona y propilenglicol. | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| NZ602990A (en) | Ganglioside micelles as a delivery system for hydrophobic drugs | |
| BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
| WO2016014680A8 (en) | Oral transmucosal compositions including aromatase inhibitors for low testosterone levels in men | |
| WO2011151786A3 (en) | Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer | |
| JP2018512395A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |